Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417634 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sunyoung Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea. Hauptthemen laut MEDLINE: T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Science and Technology, National Research Foundation of Korea, Korea Drug Development Fund.
Abstract (Originalsprache)
Efforts to treat cancer using chimeric antigen receptor (CAR)-T therapy have made astonishing progress and clinical trials against hematopoietic malignancies have demonstrated their use. However, there are still disadvantages which need to be addressed: high costs, and side effects such as Graft-versus-Host Disease (GvHD) and Cytokine Release Syndrome (CRS). Therefore, recent efforts have been made to harness the properties of certain immune cells to treat cancer—not just T cells, but also natural killer (NK) cells, macrophages (Mφ), dendritic cells (DC), etc. In this paper, we will introduce immune cell-based cellular therapies that use various immune cells and describe their characteristics and their clinical situation. The development of immune cell-based cancer therapy fully utilizing the unique advantages of each and every immune cell is expected to enhance the survival of tumor patients owing to their high efficiency and fewer side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
- Division of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
- KRIBB School of Bioscience, Korea University of Science and Technology (UST), Daejeon 34113, Republic of Korea.
ORCID-Profile: Tae-Don Kim
Förderung
- National Research Council of Science and Technology
- National Research Foundation of Korea
- Korea Drug Development Fund
- KRIBB Research Initiative Program, “R&D Convergence Program” of the National Research Council of Science and Technology
- National Research Foundation
Zitieren
APA
Lee, S., & Kim, T. D. (2023). Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417634
Vancouver
Lee S, Kim TD. Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417634
BibTeX
@article{Lee2023,
author = {Lee, Sunyoung and Kim, Tae-Don},
title = {Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417634}
}
EUVIMED